Atormac
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1711  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,249 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 »  Introduction
 »  Patients and Methods
 »  Results
 »  Discussion
 »  Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed6063    
    Printed131    
    Emailed0    
    PDF Downloaded112    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 


 
Table of Contents    
TOPIC OF THE ISSUE: ORIGINAL ARTICLE
Year : 2011  |  Volume : 59  |  Issue : 2  |  Page : 248-253

Factors predicting progression of low-grade diffusely infiltrating astrocytoma


1 Department of Neurosurgery, NIMHANS, Bangalore, India
2 Department of Neuropathology, NIMHANS, Bangalore, India

Date of Submission01-Sep-2010
Date of Decision09-Nov-2010
Date of Acceptance01-Feb-2011
Date of Web Publication7-Apr-2011

Correspondence Address:
Vani Santosh
Department of Neuropathology, NIMHANS, Bangalore - 560 029
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.79137

Rights and Permissions

 » Abstract 

Background: Low-grade diffuse astrocytoma (DA) is considered benign tumor (World Health Organization [WHO] grade II), but it has an inherent tendency for malignant progression, which is quite variable. Aim: To identify malignant progression in an individual case of DA, we studied the clinico-radiological and immunohistochemical factors and correlated with progression of DA at a dedicated tertiary level neurosciences centre NIMHANS, Bangalore, India. Patients and Methods: Consecutive adult patients who had undergone tumor decompression for lobar supratentorial DA at our institute from 1994 to 1998 were retrospectively selected and followed up for clinico-radiological progression. The clinico-radiological and histomorphological features were studied. With the use of immunohistochemistry, proliferation index [MIB-1 labeling index (LI)], p53 protein expression, microvessel density (MVD) count [assessed using anti-CD34 antibody] were analyzed and correlated with progression-free survival (PFS) Results: There were 13 patients. Mean age was 34 years. The most common presenting symptom was seizures. The median follow-up was 54 months. There were four recurrences, with median interval of 75 months. Eight patients received radiotherapy. Younger patients (<40 years), seizure as the presenting symptom and postoperative radiotherapy were associated with longer PFS, while gemistocytic morphology (>20% gemistocytic cells), MVD value >20 correlated with shorter PFS, albeit statistically insignificant. MIB1 LI did not correlate with recurrence pattern. Moreover, p53 LI > 10% correlated with early progression (P = 0.04). Conclusion: Our study highlights some of the clinical, histological and immunohistochemical parameters that predict progression on DA. Validation on a larger sample may be useful to plan appropriate treatment in an individual case.


Keywords: Diffuse astrocytoma progression, MIB-1, MVD, p53


How to cite this article:
Ranjan M, Santosh V, Tandon A, Anandh B, Sampath S, Devi B I, Chandramouli B A. Factors predicting progression of low-grade diffusely infiltrating astrocytoma. Neurol India 2011;59:248-53

How to cite this URL:
Ranjan M, Santosh V, Tandon A, Anandh B, Sampath S, Devi B I, Chandramouli B A. Factors predicting progression of low-grade diffusely infiltrating astrocytoma. Neurol India [serial online] 2011 [cited 2019 Oct 19];59:248-53. Available from: http://www.neurologyindia.com/text.asp?2011/59/2/248/79137



 » Introduction Top


Low-grade diffuse astrocytoma (World Health Organization [WHO] grade II) constitutes a minor group among diffusely infiltrating astrocytomas. These tumors have an inherent tendency of malignant transformation to a higher grade (WHO grade III/IV), which is highly variable. [1] Some clinical factors are known to determine prognosis of these patients, [2],[3],[4],[5],[6],[7],[8] but to date, no biological marker has been identified that unambiguously stratifies the individual patient at risk for malignant progression.

One of the most frequent and earliest genetic alterations recognized to occur in these tumors is the p53 mutation. [9],[10] However, the prognostic relevance of p53 mutation is still debated. [9],[11],[12],[13],[14] Some studies have shown that the frequency of p53 mutation is higher in tumors that progress to anaplastic astrocytoma and

glioblastoma. [11],[15],[16] Further, with respect to growth and progression of tumor, angiogenesis plays an important role. The extent of angiogenesis as reflected by the microvascular density count in low-grade astrocytomas has predicted the prognosis and, importantly, subsequent malignant transformation of the tumor. [17]

In order to identify prognostic markers that govern early recurrence and, in turn, the progression in low-grade diffuse astrocytoma, we have assessed some clinical and histopathological features of diffuse astrocytoma (DA) along with the tumor's proliferative activity (reflected by MIB-1 labeling) and p53 immunoreactivity in the present study. We have also evaluated microvascular density counts in these tumors. The results were correlated with the progression of these tumors.


 » Patients and Methods Top


Consecutive adult patients (>18 years) with lobar supratentorial, DA (WHO grade II), who underwent surgical decompression at the National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India, between 1994 and 1998 were retrospectively selected and followed up for clinico-radiological progression. Clinico-radiological progression was defined as worsening of symptoms with corroborative evidence of radiological recurrence in these patients. All the cases diagnosed as low-grade DA (n = 38) during this period were collected. The formalin-fixed, paraffin-embedded blocks of histologically diagnosed cases were retrieved and fresh sections were prepared and reviewed by a single neuropathologist (VS). Twenty-five of these cases noted to have smaller foci of hypercellularity and increased mitosis suggesting progression within the tumor were excluded from the study and hence the study was conducted on 13 patients who satisfied stringent criteria of WHO grade II pure DA . The clinical data, imaging, operative findings, and patient outcome, including the incidence of recurrence and patient management were documented from the hospital records. Follow-up data were obtained by personal evaluation at the outpatient clinic or by postal communication through a designed questionnaire.

The specific histological features were presence of gemistocytes, stromal microcystic change (MCC), and tumor infiltrating lymphocytes (TIL).

Immunohistochemistry

Paraffin sections of thickness 5 μ were collected on silane-coated slides and subjected to immunohistochemistry (IHC) using monoclonal antibodies: MIB-1 (Ki-67-specific monoclonal antibody; DAKO, Denmark, Dilution- 1:50), p53 (Dako, Denmark; Clone-DO7 Dilution-1:200), CD34 (Biogenex, USA; Clone-QBEND/10, Dilution-1:40). After preliminary standard processing steps, the sections were incubated with the primary antibody for 2 hours followed by secondary antibody; super-sensitive non-biotin HRP Detection Kit (Biogenex) for 1 hour. Chromogenic substrate used was 3,3'-diaminobenzidine (Sigma, Germany). Sections were counterstained with hematoxylin. Standard positive controls were used for MIB-1 and CD34 stainings. For p53 staining, glioblastoma sections that previously showed strong immunoreactivity were used as positive controls. A negative control slide in which the primary antibody is excluded was incorporated with each batch of slides. The staining pattern was nuclear for MIB-1 and p53 and cytoplasmic for CD34. MIB-1 and p53 immunolabeling were scored by a visual semiquantitative method and the labeling index (LI) was calculated as the percentage positivity after counting 1,000 tumor cells. Microvascular density (MVD) counting was done on CD34-stained slides. MVD was defined as the number of single-layered microvessels (venules and capillaries) counted under 200X magnification (20 objective lens and 10 eye piece). Within each tumor specimen, four separate randomly selected sites were counted and then averaged for the individual case as described earlier. [18]

Statistical analysis

Data was analyzed with SPSS 15 software. Data appear as mean ±SD for quantitative variables. Kaplan-Meier survival curves with log-rank statistical test was used to obtain median survival rates and correlate the histological features, MIB-I LI and p53 LI and MVD count with progression. When applicable, independent t test was applied to compare between the two groups. P < 0.05 was considered significant.


 » Results Top


The study group included 13 adult patients. The mean age of patients was 34.07±8.27 years. Three-fourths of the patients were male. Median follow-up was 54 months. There were four recurrences [Figure 1]c, with median recurrence period being 75 months. Younger patients (under the age of 40 years) had a longer progression-free interval (PFS) [Table 1].
Figure 1: (a) Preoperative scan of diffuse astrocytoma; (b) Postoperative scan with gross total decompression; and (c) Recurrence at 52-week follow-up.

Click here to view
Table 1: Correlation of clinical variables with progression-free survival

Click here to view


The mean duration of symptoms was 22 months and seizure (62%) was the most common symptom. This was associated with longer PFS [Table 1]. The most common locations were frontal and temporal lobes (31% each) and a majority of tumors were hypodense and nonenhancing on cranial computed tomography (CT) scan [Figure 1]a. However, minimal contrast enhancement was evident in about 23% of the cases. However, the latter feature had no association with PFS. Almost 70% patients underwent total/gross total decompression [Figure 1]b. The extent of resection did not correlate with PFS. Eight patients received postoperative radiotherapy, which was associated with longer PFS. Taken together, we noted that the age of patients below 40 years, presence of seizures, and administration of radiotherapy were clinical factors associated with longer PFS in diffuse astrocytoma, albeit statistically insignificant [Table 1].

Among histological features that were considered for analysis, patients whose tumors revealed predominantly gemistocytic cells (39%) had a shorter PFS (P = 0.94), albeit statistically insignificant [Figure 2]a [Table 2]. The presence of MCC (77%) and TIL (38%) in the tumor did not correlate with PFS.

[Table 3] summarizes the immunohistochemical profile. MIB-1 labeling index (MIB 1 LI) was generally low [Figure 2]b. The means that MIB1 LI was 2.52±0.57.There was no prognostic cut-off value for MIB-1 LI in our series. Immunoreactivity for p53 protein was seen in nine cases [Figure 2]c. The mean p53 LI was 11.69±9.64. There was only one recurrence in p53-negative tumors, with a recurrence interval of 125 months, while there were three recurrences in p53-positive tumors, with a significantly shorter median recurrence interval of 67 months. We noted that a p53 LI>10% was associated with shorter PFS (P = 0.04) [Figure 3] [Table 4].
Figure 2: (a) Predominant gemistocytic astrocytes in DA, H and E, ×160; (b) Occasional Ki67 staining of tumor cells nuclei, ×160; (c) p53 labeling showing moderate p53 expression of the tumor cell nuclei, ×160; and (d) Labeling of tumor vasculature by anti-CD34 antibody, ×160

Click here to view
Figure 3: Kaplan-Meier survival curve correlating p53 reactivity

Click here to view
Table 2: Correlation of gemistocytic astrocytoma with progression-free survival

Click here to view
Table 3: Immunohistochemical profile of tumors

Click here to view
Table 4: Correlation of p53 expression and MVD with progression-free survival

Click here to view


The mean MVD count was 35.24±17.11 in our series [Figure 2]d. An MVD count in the tumor of more than 20 was associated with early recurrence in patients. However, this did not reach statistical significance (P=0.55) [Table 4]. The mean value of MVD in the enhancing and non-enhancing tumor was 28.05±20.14 and 37.27±16.75, respectively. However, there was no statistically significant correlation of the MVD values between enhancing and non-enhancing tumors (P = 0.46; independent t test).


 » Discussion Top


Diffuse astrocytomas comprise 10-15% of all astrocytic brain tumors and have a longer survival when compared to anaplastic astrocytoma and glioblastoma. However, the biological behavior of each tumor is unpredictable and prognostication of an individual case is one of the most difficult tasks in neuro-oncology. A number of factors have been implicated as early prognostic indicators of malignant progression, but have shown inconsistent results.

Clinical variables

Among the clinical variables, age is a well-established prognostic factor for survival in low-grade gliomas, including diffuse astrocytoma. [2],[3],[4],[5],[6],[7] A definite association between age and survival has been established, with the prognosis being worse in older patients (>40 years). [6] In keeping with this observation, we also noted patients below the age of 40 years to have a better, PFS even though the difference did not reach statistical significance, which could be explained by the small number of cases in our study. Similarly, presence of seizures was associated with longer PFS, a feature noted in earlier study also. [2] While Pignatti et al. have noted seizures to be associated with longer survival only in univariate, but not in multivariate analysis. [6]

Diffuse astrocytomas are generally non-enhancing tumors or show minimal contrast enhancement on CT scan. [19] In our series, contrast enhancement was evident in one-fourth of cases; however, this feature had no effect on PFS.

Maximum surgical excision of DA tumors is an established favorable prognostic factor. [20] It has been noted earlier that the risk of recurrence in low-grade gliomas minimizes, and PFS increases when the residual tumor volume postoperatively is small (<10 cm 3 ), [21] though this feature failed to show conclusive results in another study. [22] We were also unable to correlate the extent of tumor resection with patient survival (P = 0.55). The major drawback in assessing the prognostic value of extent of resection in various earlier studies is the non-quantitative assessment and the retrospective design of the study, similar to ours.

With respect to adjuvant therapy, we have noted that administration of radiotherapy is associated with longer PFS, consistent with EORTC Trial 22845, [23] though it was not statistically significant. Another study confirms postoperative radiotherapy to have an independent prognostic value for PFS. These authors even recommend postoperative radiotherapy for all patients with low-grade gliomas regardless of the extent of surgery and the histological subtypes. [24]

Histopathological variables

In earlier studies, prognosis in DA has been correlated with various histological features. The gemistocytic variant has been associated with rapid progression to higher grade (WHO grade III/IV), when compared to fibrillary or protoplasmic variants. [25] The biological basis of this is not clear since gemistocytes by themselves are terminally differentiated astrocytes and have a low proliferative activity. However, these gemistocytes have been noted to carry a higher p53 mutation, and this has been suggested to be the underlying cause for rapid progression of gemistocytic astrocytomas. [26] Presence of a higher percentage (>20%) of gemistocytes in DA has been associated with shorter survival. Some authors even suggest gemistocytic astrocytoma to be considered as a variant of anaplastic astrocytoma (WHO grade III) [27] In the present study, when gemistocytes comprised more than 20% cells in the tumor, we noted shorter PFS , although it was not statistically significant, which could be influenced by the small number of cases.

Other histological features that we correlated with patient survival were microcystic change (MCC) and tumor infiltrating lymphocytes (TIL). MCC has shown to correlate with better survival in DAs. [28] Even though MCC was noted in a large number of tumors in our series, it did not influence PFS. Similarly, we could not find any prognostic correlation between TIL and patient survival. TIL has been observed in 28-52% of gliomas as determined on surgical biopsy material. [29] T-Lymphocytes constitute a large portion of these cells and studies have shown that these T-cells are small, nonblastic and negative for activation antigens. [30] The significance of TIL in astrocytomas with respect to tumor behavior is unclear. Earlier studies have shown that astrocytoma growth does not seem to be dramatically modified by these cells, implying that either the infiltration is insufficient, or that tumor cells are resistant, or that TIL are functionally inactive. [31]

Immunohistochemical variables

MIB 1 LI


Analysis of a wide range of astrocytic tumors of different grades among various studies has shown an overall correlation of tumor cell proliferation with clinical outcome. [32],[33],[34],[35],[36],[37],[38],[39],[40],[41],[42],[43],[44] Several studies have given a cutoff value for MIB-1 (Ki 67 monoclonal antibody) labeling index (LI) that helps prognosticate DA (WHO II), which is quite variable with a range of 2-8%. [38],[39],[43] However, this correlation was not replicated in all studies. In their study of 96 grade II diffuse astrocytomas, Hilton et al.[45] did not observe any prognostic significance. We have also not observed this correlation. This lack of correlation of MIB1-LI and patient survival is probably due to the fact that the range of MIB-1 labeling in DA tumors is so low and uniform throughout the tumor that it fails to differentiate individual tumors in terms of behavior and prognosis.

p53

The effect of alteration of the p53 gene on patient prognosis in low-grade astrocytomas has revealed ambiguous results. While some studies highlight the association with poor prognosis in diffuse astrocytoma, [12] others have not shown any correlation between p53 mutation or immunoreactivity with survival. [9],[13],[14] To perplex the issue, one study has established a better survival in p53-positive astrocytomas. [11] Watanabe et al., in 1997, noted significant concordance between p53 mutations and p53 protein accumulation. They found that a higher p53 LI reflects more aggressive behavior of the tumor and noted progressive increase in the p53 LI with the increasing grade of the tumor. [15]

We have noted p53 immunoreactivity in 69% of cases. The number of immunolabeled nuclei in individual tumors is in the range of 10-30%. Interestingly, we found that tumors with p53 LI of more than 10% correlated with shorter recurrence interval (P = 0.04). We have also observed the significant difference in the recurrence period between p53-negative and p53-positive tumors (125 vs 67 months). This underscores the importance of p53 immunoreactivity in low-grade astrocytomas.

Microvascular density

Microvascular density (MVD) represents the degree of tumor neovascularization, and it has been found to be an important indicator of malignant behavior in many human neoplasms. The relationship of tumor microvascular density to patient prognosis has been shown in diverse brain tumors of varied grades. [46],[47] Abdulrauf et al.[17] have also shown MVD to be an independent prognostic marker of survival in fibrillary low-grade astrocytomas. In the present study, we observed that MVD count of more than 20 are associated with shorter PFS, although the value was not statistically significant, probably because of the fewer number of cases.


 » Conclusion Top


Taken together, our study shows that in patients aged below 40 years, seizures as the presenting symptom and administration of postoperative radiotherapy are favorable prognostic factors. In contrast, gemistocytic morphology, p53 overexpression and microvascular density count of more than 20 are unfavorable factors, which are indicative of early recurrence and aggressive behavior of the tumor. Since this information is essential in predicting the behavior of the tumor, validation of these results on larger sample sets would be useful, and thus may influence the clinical decision-making process.

 
 » References Top

1.Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery 1996;38:872-8  Back to cited text no. 1
    
2.Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, et al. Supratentorial lowgrade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997;15:1294-301.   Back to cited text no. 2
    
3.van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: Prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 1998;64:581-7.   Back to cited text no. 3
    
4.Laws ER, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 1984; 61:665-673.  Back to cited text no. 4
    
5.Nicolato A, Gerosa MA, Fina P, Iuzzolino P, Giorgiutti F, Bricolo A. Prognostic factors in low-grade supratentorial astrocyomas: A uni-multivariate statistical analysis in 76 surgically treated patients. Surg Neurol 1995;44:208-21.  Back to cited text no. 5
    
6.Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076-84.  Back to cited text no. 6
    
7.Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, et al. Survival, prognostic factors, and therapeutic efficacy in low grade glioma: a retrospective study in 379 patients. J Clin Oncol 1997;15:3129-40.  Back to cited text no. 7
    
8.Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization grade 2 astrocytomas and oligoastrocytomas: A new pattern of prognostic factors. Cancer 1997;79:370-79.   Back to cited text no. 8
    
9.Kraus JA, Bolln C, Wolf HK, Neumann J, Kindermann D, Fimmers R, et al. TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 1994;10:143-9.  Back to cited text no. 9
    
10.Louis DN.The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994;53:11-21.  Back to cited text no. 10
    
11.van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG. p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst 1994;86:1011-7.  Back to cited text no. 11
    
12.Chozick BS, Pezzullo JC, Epstein MH, Finch PW. Prognostic implications of p53 overexpression in supratentorial astrocytic tumors. Neurosurgery 1994;35:831-7.  Back to cited text no. 12
    
13.Rainov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschläger C, Heidecke V, et al. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997;35:13-28.  Back to cited text no. 13
    
14.al-Sarraj S, Bridges LR. P53 immunoreactivity in astrocytomas and its relationship to survival. Br J Neurosurg 1995;9:143-9.  Back to cited text no. 14
    
15.Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, et al. Incidence and timing of p53 mutations during astrocytomas progression in patients with multiple biopsies. Clin Cancer Res 1997;3:523-530.  Back to cited text no. 15
    
16.Sarkar C, Ralte AM, Sharma MC, Mehta VS. Recurrent astrocytic tumors- a study of p53 immunoreactivity and malignant progression. Br J Neurosurg 2002;16:335-42.   Back to cited text no. 16
    
17.Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytomas. J Neurosurg 1998;88:513-520.   Back to cited text no. 17
    
18.Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-80.   Back to cited text no. 18
    
19.Silverman C, Marks JE. Prognostic significance of contrast enhancement in low-grade astrocytomas of the adult cerebrum. Radiology 1981;139:211-3.   Back to cited text no. 19
    
20.Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95:735-45.   Back to cited text no. 20
    
21.Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784-91.   Back to cited text no. 21
    
22.Miralbell R, Balart J, Matias-Guiu X, Molet J, Ariza A, Craven-Bartle J. Radiotherapy for supratentorial low-grade gliomas: results and prognostic factors with special focus on tumour volume parameters. Radiother Oncol 1993; 27:112-6.   Back to cited text no. 22
    
23.Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002;52:316-24.   Back to cited text no. 23
    
24.Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY. Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br Jr Radiol 2005;78:230-5.   Back to cited text no. 24
    
25.Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H. Role of gemistocytes in astrocytoma progression. Lab Invest 1997;76:277-84.   Back to cited text no. 25
    
26.Avninder S, Sharma MC, Deb P, Mehta VS, Karak AK, Mahapatra AK, et al. Gemistocytic astrocytomas: Histomorphology, proliferative potential and genetic alterations--a study of 32 cases. J Neurooncol 2006;78:123-7.   Back to cited text no. 26
    
27.Krouwer HG, Davis RL, Silver P, Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg 1991;74:399-406  Back to cited text no. 27
    
28.Schiffer D, Chiò A, Giordana MT, Leone M, Soffietti R. Prognostic value of histologic factors in adult cerebral astrocytomas. Cancer 1988;61:1386-93.   Back to cited text no. 28
    
29.Takeuchi J, Barnard RO. Perivascular lymphocytic cuffing in astrocytomas. Acta Neuropathol 1976;35:265-71.  Back to cited text no. 29
    
30.Miescher S, Whiteside TL, de Tribolet N, von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers. J Neurosurg 1988;68:438-48.  Back to cited text no. 30
    
31.Dietrisch P.Y, Walter PR, Calzascia T, de Tribolet N. Immunology for brain tumor and implication for immunotherapy. In, Kaye AH, Laws EJ Editors. Brain tumors. An encyclopedic approach. 2nd edition. London, Harcourt Publishers Ltd. 2001. p. 135-50.   Back to cited text no. 31
    
32.Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immuno reactivity in human central nervous system tumors: A study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.  Back to cited text no. 32
    
33.Khalid H, Shibata S, Kishikawa M, Yasunaga A, Iseki M, Hiura T. Immunohistochemical analysis of progesterone receptor and Ki-67 labeling index in astrocytic tumors. Cancer 1997;80:2133-40.  Back to cited text no. 33
    
34.Sallinen PK, Haapasalo HK, Visakorpi T, Helén PT, Rantala IS, Isola JJ, et al. Prognostication of astrocytoma patient survival by Ki- 67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994;174:275-82.   Back to cited text no. 34
    
35.Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;77:373-80.  Back to cited text no. 35
    
36.Di X, Nishizaki T, Harada K, Kajiwara K, Nakayama H, Ito H, et al. Proliferative potentials of glioma cells and vascular components determined with monoclonal antibody MIB-1. J Exp Clin Cancer Res 1997;16:389-94.   Back to cited text no. 36
    
37.Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997;56:857-65.   Back to cited text no. 37
    
38.McKeever PE, Strawderman MS, Yamini B, Mikhail AA, Blaivas M. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol 1998;57:931-6.   Back to cited text no. 38
    
39.Schiffer D, Cavalla P, Chiò A, Richiardi P, Giordana MT. Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 1997;34:31-5.   Back to cited text no. 39
    
40.Eneström S, Vavruch L, Frånlund B, Nordenskjöld B. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie 1998;44:25-30.   Back to cited text no. 40
    
41.Ralte AM, Sharma MC, Karak AK, Mehta VS, Sarkar C. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors. Pathol Oncol Res 2001;7:267-78.   Back to cited text no. 41
    
42.Torp SH. Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neouropathol 2002;21:252-7.   Back to cited text no. 42
    
43.Torp SH, Alsaker M. Ki-67 immunoreactivity, basic fibroblast growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract 2002;198:261-5.   Back to cited text no. 43
    
44.Neder L, Colli BO, Machado HR, Carlotti CG Jr, Santos AC, Chimelli L, et al. MIB-1 labeling index in astrocytic tumors - a clinicopathologic study. Clin Neuropathol 2004;6:262-70.   Back to cited text no. 44
    
45.Hilton DA, Love S, Barber R, Ellison D, Sandeman DR. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 1998;42:724-9.   Back to cited text no. 45
    
46.Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82-6.  Back to cited text no. 46
    
47.Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72.  Back to cited text no. 47
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]

This article has been cited by
1 Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target?
Jian-jun Sun,Zhen-yu Wang,Ling-song Li,Hai-yan Yu,Yong-sheng Xu,Hai-bo Wu,Yi Luo,Bin Liu,Mei Zheng,Jin-long Mao,Xiao-hui Lou
Neural Regeneration Research. 2015; 10(2): 244
[Pubmed] | [DOI]
2 Vascular endothelial growth factor and KIT expression in relation with microvascular density and tumor grade in supratentorial astrocytic tumors
Thaís Heinke,Kleber Simões do Espiríto Santo,Adhemar Longatto Filho,João Norberto Stavale
Acta Cirurgica Brasileira. 2013; 28(1): 48
[Pubmed] | [DOI]
3 Vascular endothelial growth factor and KIT expression in relation with microvascular density and tumor grade in supratentorial astrocytic tumors
Heinke, T. and Santo, K.S.D.E. and Filho, A.L. and Stavale, J.N.
Acta Cirurgica Brasileira. 2013; 28(1): 48-54
[Pubmed]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow